MKI67 and neoplasm: Reproducible data at a I-B level of evidence (LoE) suggest that Ki67 is a prognostic marker in early stage breast cancer [8], as well as a positive predictive factor for adjuvant chemotherapy [9], especially in patients with luminal B tumours [10].